Visual Hallucinations in Lewy Body Dementia

A Phase 2, multi-center, double-blind, placebo-controlled crossover study evaluating nelotanserin in subjects with dementia with Lewy bodies (DLB) suffering from visual hallucinations.

The safety, efficacy, and tolerability of nelotanserin at doses of 40 mg and 80 mg are being evaluated over a 4-week treatment period in approximately 20 subjects with DLB. This is a crossover study so every subject will receive placebo for 4 weeks and nelotanserin for 4 weeks, but neither the subjects nor their physicians will know which treatment is being administered. The primary outcome measures are safety and tolerability. The frequency and severity of visual hallucinations over a 4-week treatment period are a secondary outcome measure. Subjects who complete the study are eligible to receive nelotanserin in an extension study.

Compound:
Nelotanserin

Therapeutic Area(s):

  • Dementia with Lewy bodies (DLB)

For More Information:
ClinicalTrials.gov